首页> 外文期刊>BMC Medical Ethics >South Africa’s new standard material transfer agreement: proposals for improvement and pointers for implementation
【24h】

South Africa’s new standard material transfer agreement: proposals for improvement and pointers for implementation

机译:南非的新标准材料转移协议:实施提案和实施指针

获取原文
           

摘要

Whenever South African (SA) research institutions share human biological material and associated data for health research or clinical trials they are legally compelled to have a material transfer agreement (MTA) in place that uses as framework the standard MTA newly gazetted by the South African Minister of Health (SA MTA). The article offers a legal analysis of the SA MTA and focuses on its substantive fit with the broader legal environment in South Africa, and the clarity and practicality of its terms. The following problematic aspects of the SA MTA are highlighted: (a) Where only data and no human biological material are transferred, the SA MTA does not apply, leaving a lacuna; (b) Health Research Ethics Committees are required to be parties to a MTA despite it being outside their legal mandate and undermining their oversight function; (c) the SA MTA’s consent provisions are not aligned with extant law; and, similarly, (d) its provision on donor ownership is misaligned with extant law; (e) its creation of fictitious performance can only cause frustration on the part of an injured party; (f) its benefit-sharing provision is vague and will have little practical effect; (g) its dispute-resolution provisions fail to adequately protect South African research institutions and research participants; (h) it fails to provide substantive guidance regarding intellectual property as its provisions relating to intellectual property may cause practical problems; and, finally, (i) its data privacy provision is insufficiently specific, is overbroad, and fails to provide terms that in general would facilitate the international sharing of human biological material and associated data in terms of existing privacy law. While some of the problematic aspects of the SA MTA are intricate and require consultative processes with stakeholders and others, to develop comprehensive solutions, most of the problematic aspects can be resolved immediately through amendments by the South African Minister of Health. The formulation of such amendments is proposed and, where possible, interim measures are suggested that may ameliorate the problems presented by the SA MTA.
机译:每当南非(SA)研究机构分享人类生物材料和相关的健康研究数据或临床试验时,他们就是在法律上被迫拥有重大转移协议(MTA),以适用于南非部长新刊登的标准MTA的框架健康(SA MTA)。本文对SA MTA提供了法律分析,并专注于与南非更广泛的法律环境的实质性合适,以及其条款的清晰度和实用性。突出显示SA MTA的以下问题方面:(a)仅在其中转移数据和没有人体生物材料,SA MTA不适用,留下一只曲线仪; (b)卫生研究伦理委员会仍需要成为MTA的缔约国,尽管它超出了其法律授权并破坏其监督职能; (c)SA MTA的同意条款与现存法不一致;而且,同样,(d)其关于捐助者所有权的规定与现存法没有崩溃; (e)它的创造虚构的表现只能造成受伤党的挫折; (f)其惠益分享规定含糊不清,实际效果几乎没有; (g)其争议解决规定未能充分保护南非研究机构和研究参与者; (h)它未能为知识产权提供实质性指导,因为其与知识产权有关的规定可能导致实际问题;最后,(i)其数据隐私规定是不够的,是跨越的,并且未能提供术语,这通常会在现有的隐私法方面有助于国际分享人体生物材料和相关数据。虽然SA MTA的一些有问题的方面是复杂的,并且需要与利益攸关方和其他利益相关者和其他人的咨询流程,以制定全面的解决方案,但大多数有问题的方面都可以通过南非卫生部长的修正立即解决。提出了此类修订的制定,并在可能的情况下,建议可能会改善SA MTA所呈递的问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号